ESMO Hot Topic: Success Imminent in MATTERHORN Phase III Study, Neoadjuvant Durvalumab Shows Promising Progress for Gastric Cancer pCR
Editor's Note: The 2023 ESMO Annual Meeting took place from October 20th to 24th in Madrid, Spain. As a highly authoritative annual event in the field of oncology, it unveils…